Company research

CTKB · NASDAQ

Cytek Biosciences Inc

Healthcare · Medical Devices

$6.30

+2.61%

Close on Oct 29, 2026

Research data through 2026-10-28

Long-term research evidence only. No price targets, no trading signals, no recommendations.

Free research · no account required

Pro Investor Academy research

Research data through Oct 28, 2026. Research is updated periodically, not in real time.

Quality

25

of 100 · stored research reading

Stored Quality research reads 25 of 100, in the weaker band of the covered universe. This is a research reading about business durability, not a view on the share price.

Quality research measures durability of the business itself from stored fundamentals: balance-sheet strength, profitability consistency and cash generation. It is a research reading, not a prediction of future returns.

How this is measured

Fundamental Momentum

—

Not currently available

Not currently available. Pro Investor Academy holds no current Fundamental Momentum measurement for this company.

Fundamental Momentum research measures the direction of recently reported company fundamentals compared with the company's own history. It describes reported change, not future price movement.

How this is measured

Capital Returns

Weak

16

of 100 · stored research reading

Stored Capital Returns research reads 16 of 100, recorded as weak. No dividend is recorded for this company, so the reading rests on buybacks and dilution control. Share count has increased at about 32.4% a year in the stored window.

Capital Returns research measures how a company has actually returned cash to shareholders: dividend record, buyback effectiveness, dilution control and how those payments were funded.

How this is measured

Investor intelligence

What Investor adds for CTKB

The research below is part of Investor membership. Values are withheld from this page entirely — nothing premium is loaded into it. Start the free trial and the intelligence you asked for unlocks right here.

Investor

See how this company ranks.

Unlock its Pro Investor Score and ranking across the research universe.

7 days · No credit card required

Investor

Understand the risk before you invest.

Unlock Risk Intelligence, Price Risk, and Market Confirmation.

7 days · No credit card required

Investor

Know why, not just what.

Unlock the Pro Research Brief with What Changed & Why, research history and tensions.

7 days · No credit card required

Investor

See what professional investors are reporting.

Unlock Pro Investor Intelligence: disclosed professional-manager and insider activity beside company research.

7 days · No credit card required

Investor

Ask the research.

Unlock Pro Investor AI to ask questions grounded in Pro Investor Academy research and evidence.

7 days · No credit card required

Investor

Keep researching after today.

Save companies and monitor how their research changes over time.

7 days · No credit card required

Explore other companies in this industry. These are objective industry neighbours, not suggested alternatives.

Want to know what qualified today?

Pro Investor Academy continuously applies its research rules across the eligible universe and surfaces a small number of investments for deeper research when they qualify.

Appears in

Rule-based membership

Membership means the company satisfied a published rule on the latest research build. It is not a recommendation.

Learn the metrics on this page

Plain-English definitions, with the formula and the limitations of each measure.

In the company’s own words

What this company does

We are a leading cell analysis solutions company advancing the next generation of research and clinical tools with our novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells ("Full Spectrum Profiling" or "FSP" technology). Our goal is to become the premier cell analysis company through continued innovation that facilitates scientific advances in biomedical research and clinical applications.

Biological systems are highly complex, and scientists are challenged by the multitude of questions that remain unanswered. Analysis at the single-cell level is essential to understand these complex systems. Identifying the correct cell in the context of a given biological question can have profound implications for drug development and health care decisions. It is essential to correlate information derived from multiple cell analysis approaches and to translate what is known at the gene level to the actual cell function. As a result, there is growing demand for deep content through high dimensional cell analysis and for solutions that can provide a complete picture of cellular biological processes and interactions. To achieve this, scientists need to phenotype and isolate rare events or unique populations down to the single-cell level through highly resolvable multi-dimensional cell analysis. While flow cytometry is a widely used tool for single cell analysis, conventional flow cytometry, mass cytometry and early approaches to spectral flow cytometry technologies have historically been challenged due to limited dimensionality, sub-optimal resolution, low throughput, high cost for performance and/or significant technical expertise required to operate systems.

Our patented FSP technology optimizes sensitivity and accuracy through its unique optical and electronic designs that utilize an innovative method of light detection and distribution to a specifically selected number and type of detectors. This patented optics design enables researchers to effectively collect the full range of light emissions in an extremely compact space, resulting in higher resolution and enabling the development of highly complex assays with 50 different colors (individual fluorochromes), supporting 50 biomarkers within just a single tube.

Our FSP cell analyzers, the Cytek Aurora , Northern Lights , and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies by providing a higher level of multiplexing with exquisite sensitivity, more flexibility and increased efficiency, all at a lower cost for performance. Additionally, our Cytek Aurora cell sorter ("Aurora CS system") leverages our FSP technology to further broaden our potential applications across cell analysis by enabling the same number of parameters with the same sensitivity as the Cytek Aurora and Cytek Aurora Evo cell analyzer systems. Each system is supported by our highly intuitive, proprietary embedded SpectroFlo software, our reagents, and our service offerings to provide a comprehensive, end-to-end platform of solutions for our customers.

Quoted from the business section of this company’s 10-K filed February 26, 2026. Read the filing

General research only. Not personalized advice. Public filings may be delayed, amended, incomplete, or reflect positions that have changed since the reporting date.